Label: VISTARIL- hydroxyzine pamoate capsule VISTARIL- hydroxyzine pamoate suspension 

  • Label RSS
  • NDC Code(s): 0069-5410-66, 0069-5420-66, 0069-5430-66, 0069-5440-93, view more
    0069-5440-97
  • Packager: Pfizer Laboratories Div Pfizer Inc
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated 05/14

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Hydroxyzine pamoate is designated chemically as 1-(p-chlorobenzhydryl) 4- [2-(2-hydroxyethoxy) ethyl] diethylenediamine salt of 1,1′-methylene bis (2 hydroxy- 3-naphthalene carboxylic acid).

    Inert ingredients for the capsule formulations are: hard gelatin capsules (which may contain Yellow 10, Green 3, Yellow 6, Red 33, and other inert ingredients); magnesium stearate; sodium lauryl sulfate; starch; sucrose.

    Inert ingredients for the oral suspension formulation are: carboxymethylcellulose sodium; lemon flavor; propylene glycol; sorbic acid; sorbitol solution; water.

    Close
  • CLINICAL PHARMACOLOGY

    Vistaril® (hydroxyzine pamoate) is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines.

    Vistaril is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally. Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity. Hydroxyzine is rapidly absorbed from the gastrointestinal tract and Vistaril's clinical effects are usually noted within 15 to 30 minutes after oral administration.

    Close
  • INDICATIONS

    For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.

    Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus.

    As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.

    The effectiveness of hydroxyzine as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.

    Close
  • CONTRAINDICATIONS

    Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.

    Hydroxyzine pamoate is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

    Close
  • WARNINGS

    Nursing Mothers

    It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

    Close
  • PRECAUTIONS

    THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine, their dosage should be reduced. Since drowsiness may occur with use of the drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking Vistaril (hydroxyzine pamoate). Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased.

    Geriatric Use

    A determination has not been made whether controlled clinical studies of VISTARIL included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.

    The extent of renal excretion of VISTARIL has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.

    Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of VISTARIL and observed closely.

    Close
  • ADVERSE REACTIONS

    Side effects reported with the administration of Vistaril are usually mild and transitory in nature.

    Skin and Appendages: Oral hydroxyzine hydrochloride is associated with fixed drug eruptions in post-marketing reports.

    Anticholinergic: Dry mouth.

    Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity, including rare instances of tremor and convulsions, has been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.

    In post-marketing experience, the following additional undesirable effects have been reported: Body as a Whole: allergic reaction, Nervous System: headache, Psychiatric: hallucination, Skin and Appendages: pruritus, rash, urticaria.

    Close
  • OVERDOSAGE

    The most common manifestation of overdosage of Vistaril is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

    If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and vasopressors (do not use epinephrine as hydroxyzine counteracts its pressor action.) Caffeine and Sodium Benzoate Injection, USP, may be used to counteract central nervous system depressant effects.

    There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.

    Close
  • DOSAGE

    For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50–100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50–100 mg daily in divided doses.

    For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50–100 mg daily in divided doses.

    As a sedative when used as a premedication and following general anesthesia: 50–100 mg in adults, and 0.6 mg/kg in children.

    When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.

    As with all medications, the dosage should be adjusted according to the patient's response to therapy.

    Close
  • HOW SUPPLIED

    Vistaril Capsules (hydroxyzine pamoate equivalent to hydroxyzine hydrochloride)

    25 mg: 100's (NDC 0069-5410-66), two-tone green capsules
    50 mg: 100's (NDC 0069-5420-66), green and white capsules

    Vistaril Oral Suspension (hydroxyzine pamoate equivalent to 25 mg hydroxyzine hydrochloride per teaspoonful-5 mL): 1 pint (473 mL) bottles (NDC 0069-5440-93) and 4 ounce (120 mL) bottles (NDC 0069-5440-97) in packages of 4.

    Shake vigorously until product is completely resuspended.

    Close
  • BIBLIOGRAPHY

    Available on request.

    Close
  • SPL UNCLASSIFIED SECTION

    Rx only

    Logo

    LAB-0126-4.0
    May 2014

    Close
  • PRINCIPAL DISPLAY PANEL - 25 mg 100 Capsule Bottle Label

    NDC 0069-5410-66

    100 Capsules

    Vistaril®
    (hydroxyzine pamoate)

    25 mg*

    Pfizer
    Distributed by
    Pfizer Labs
    Division of Pfizer Inc, NY, NY 10017

    Logo
    Close
  • PRINCIPAL DISPLAY PANEL - 50 mg 100 Capsule Bottle Label

    NDC 0069-5420-66

    100 Capsules

    Vistaril®
    (hydroxyzine pamoate)

    50 mg*

    Pfizer
    Distributed by
    Pfizer Labs
    Division of Pfizer Inc, NY, NY 10017

    PRINCIPAL DISPLAY PANEL - 50 mg 100 Capsule Bottle Label
    Close
  • PRINCIPAL DISPLAY PANEL

    Image not
    available

    PRINCIPAL DISPLAY PANEL
    Close
  • PRINCIPAL DISPLAY PANEL

    Image not
    available

    PRINCIPAL DISPLAY PANEL
    Close
  • INGREDIENTS AND APPEARANCE
    VISTARIL 
    hydroxyzine pamoate capsule
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0069-5410
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    HYDROXYZINE PAMOATE (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 25 mg
    Inactive Ingredients
    Ingredient Name Strength
    D&C YELLOW NO. 10  
    FD&C GREEN NO. 3  
    FD&C YELLOW NO. 6  
    D&C RED NO. 33  
    MAGNESIUM STEARATE  
    SODIUM LAURYL SULFATE  
    SUCROSE  
    Product Characteristics
    Color GREEN (two-tone green) Score no score
    Shape CAPSULE Size 14mm
    Flavor Imprint Code Vistaril;Pfizer;541
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0069-5410-66 100 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA011459 11/28/1994
    VISTARIL 
    hydroxyzine pamoate capsule
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0069-5420
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    HYDROXYZINE PAMOATE (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 50 mg
    Inactive Ingredients
    Ingredient Name Strength
    D&C YELLOW NO. 10  
    FD&C GREEN NO. 3  
    FD&C YELLOW NO. 6  
    D&C RED NO. 33  
    MAGNESIUM STEARATE  
    SODIUM LAURYL SULFATE  
    SUCROSE  
    Product Characteristics
    Color GREEN, WHITE Score no score
    Shape CAPSULE Size 14mm
    Flavor Imprint Code Vistaril;Pfizer;542
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0069-5420-66 100 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA011459 11/15/1968
    VISTARIL 
    hydroxyzine pamoate capsule
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0069-5430
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    HYDROXYZINE PAMOATE (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 100 mg
    Inactive Ingredients
    Ingredient Name Strength
    D&C YELLOW NO. 10  
    FD&C GREEN NO. 3  
    FD&C YELLOW NO. 6  
    D&C RED NO. 33  
    MAGNESIUM STEARATE  
    SODIUM LAURYL SULFATE  
    SUCROSE  
    Product Characteristics
    Color GREEN, GRAY Score no score
    Shape CAPSULE Size 18mm
    Flavor Imprint Code Vistaril;Pfizer;543
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0069-5430-66 100 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA011459 11/15/1968 04/01/2004
    VISTARIL 
    hydroxyzine pamoate suspension
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0069-5440
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    HYDROXYZINE PAMOATE (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 25 mg  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    CARBOXYMETHYLCELLULOSE SODIUM  
    PROPYLENE GLYCOL  
    SORBIC ACID  
    SORBITOL  
    WATER  
    Product Characteristics
    Color      Score     
    Shape Size
    Flavor LEMON Imprint Code
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0069-5440-93 473 mL in 1 BOTTLE
    2 NDC:0069-5440-97 4 in 1 PACKAGE
    2 120 mL in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA011795 06/03/1959 12/01/2009
    Labeler - Pfizer Laboratories Div Pfizer Inc (134489525)
    Establishment
    Name Address ID/FEI Business Operations
    Uniion Quimico Famaceutica S.A. 460940868 MANUFACTURE(0069-5440, 0069-5430, 0069-5420, 0069-5410)
    Establishment
    Name Address ID/FEI Business Operations
    NEOLPHARMA, INC. 078709787 ANALYSIS(0069-5440, 0069-5430, 0069-5420, 0069-5410), MANUFACTURE(0069-5440, 0069-5430, 0069-5420, 0069-5410), PACK(0069-5440, 0069-5430, 0069-5420, 0069-5410)
    Close